 After 8 months of waiting for an update from the FDA, the agency finally announced a tentative approval for Aquestives Libervant. Unfortunately, the company cannot market the product. Aquestive Therapeutics recently reported their Q2 earnings, which revealed a beat on revenue with the EPS in-line with expectations. Aquestive has upped their full-year guidance for both revenue and EPS. 